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patients. Detection of HER2 amplification on DTCs could 
therefore help to better stratify patients for a more tailored 
therapy, since they would benefit from a HER2-targeted 
therapy.  © 2016 S. Karger AG, Basel 
 Background 
 Breast cancer (BC) is the most common type of cancer 
diagnosed in women who have a risk of 1 in 9 to develop 
the disease during their lifetime  [1] . According to the 
World Health Organization, BC is the fifth cause of death 
among women worldwide, being at the same time the 
most common cause of death due to cancer  [2] . The high 
mortality rate observed in BC patients is mainly connect-
ed to the high spreading capability combined with a high 
tendency to form metastasis in remote organs  [3, 4] . 
Bones are the most common targets for metastatic le-
sions generated by BC  [5–7] . Unfortunately, metastatic 
BC (MBC) is still considered incurable, and MBC pa-
tients can only benefit from palliative therapies. Preven-
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 Abstract 
 Objective: The aim of this study was to measure the human 
epidermal growth factor receptor 2 (HER2) status of dissem-
inated tumor cells (DTCs) from bone marrow (BM) aspirates 
and to assess correspondence or discrepancy with the pri-
mary tumor.  Methods: DTCs were isolated from the BM of 
156 breast cancer patients. Cytokeratin-positive DTCs were 
further analyzed by the chromogenic in situ hybridization 
method to detect HER2 gene amplification.  Results: A sig-
nificant correlation (p = 0.021) was found between the HER2 
status of DTCs and the primary tumors. Sixty-one (68.5%) pa-
tients had a corresponding status. However, a shift of phe-
notype between primary tumor and DTCs was found in the 
remaining patients.  Conclusion: This study showed a signif-
icant grade of discordance of the HER2 status between pri-
mary tumors and DTCs in the BM of a relevant subgroup of 
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tion of metastasis spreading is therefore given the highest 
priority by the scientific and medical community in the 
management of primary BC patients. Biomedical imag-
ing is considered the gold standard in prognosis and me-
tastasis monitoring, being minimally invasive and very 
sensitive  [8] . Ultrasound, positron emission tomogra-
phy, computed tomography and magnetic resonance im-
aging are commonly used in clinical practice  [9] . They 
estimate the extent of the disease following the spreading 
of the metastases, measuring their size and offering a cor-
responding evaluation of the response to treatment  [10–
12] . Nevertheless, there are alternative approaches which, 
combined to imaging, can improve the detection effica-
cy. The term minimal residual disease (MRD) refers to 
the presence of disseminated tumor cells (DTCs) and cir-
culating tumor cells (CTCs) in bone marrow (BM) and 
peripheral blood, respectively  [13, 14–16] . Different 
studies have shown that in a high number of patients 
with primary BC, cytokeratin (CK)-positive DTCs can be 
detected in BM already at the time of the first diagnosis 
 [17, 18] . The dissemination of tumor cells in the BM is 
considered responsible for the further development of 
the disease followed by metastasis  [19, 20] . Between 20 
and 45% of patients with primary BC already show single 
tumor cells in the BM at the first diagnosis: DTCs’ detec-
tion allows the identification of patients with a high risk 
of recurrence  [17, 18, 21] . The percentage of patients 
positive for DTCs rises up to 70% in case of metastasis. 
In clinical practice, the type of adjuvant therapy can be 
chosen according to different predictive factors, such as 
menopausal status, hormonal receptor status, and/or 
overexpression of the human epidermal growth factor 
receptor 2 (HER2) on the primary tumor. HER2 overex-
pression is detected in almost 30% of all BC cases, and it 
has been linked to a more aggressive form of the disease, 
a strong resistance to chemotherapy, a higher risk of re-
currence, and a shorter life expectation. The clinical im-
portance of HER2 has emerged once HER2-targeted 
agents, such as Trastuzumab, Lapatinib, and Pertuzu-
mab, have been made available  [22–24] . Usually, HER2-
positive BC patients receive an adjuvant therapy com-
bined with HER2-targeted agents when overexpression 
or gene amplification is found in the primary tumor. The 
HER2 status of DTCs is usually taken into account, as-
suming that the two cellular types (i.e. DTCs and cells of 
the primary tumor) are immunophenotypically identi-
cal. However, the HER2 status of DTCs has been shown 
to be sometimes different from the primary tumor, with 
a discrepancy between the primary tumor and DTCs of 
up to 20%  [25–27] . Importantly, patients with a HER2-
negative primary tumor are not treated with HER2-tar-
geted agents, although DTCs could be HER2 positive and 
therefore representing a potential target for tailored 
treatment options. The aim of this study was to analyze 
CK-positive DTCs for HER2 gene amplification in BM 
aspirates from a large cohort of BC patients to monitor 
any correspondence between the primary tumor and 
DTCs with respect to the HER2 status and different clin-
ical parameters.
 Material and Methods 
 Patients 
 A total of 156 BC patients from the Department of Gynecology 
and Obstetrics, Ludwig-Maximilians-University (Munich, Ger-
many) were included in this retrospective study (online suppl. ta-
ble 1; see www.karger.com/doi/10.1159/000442986 for all online 
suppl. material). All patients were treated between 1995 and 2007 
and had histologically confirmed BC according to standard clinical 
guidelines. A total of 252 BM aspirates were sampled after written 
informed consent was obtained. All protocols were approved by 
the local ethics commission and complied the Declaration of Hel-
sinki guidelines  [28] . Tumor classification was done according to 
the TNM guidelines  [29] . The HER2 status of the primary tumors 
was determined immunohistochemically (HercepTest ® ; DAKO, 
Denmark), and according to the staining intensity, it was scored 
on a 0+ to 3+ scale. Tumors with a score of 3+ were classified as 
HER2 positive, and those with a score of 2+ were further analyzed 
by fluorescence in situ hybridization (Inform ® HER-2 Kit; Ven-
tana Medical System Inc., USA, and PathVysion Kit; Abbott Mo-
lecular, USA). Specimens were classified as HER2 positive when at 
least 6 intranuclear signals per cell were detected or showed HER2 
and chromosome 17 signal ratios  ≥ 2, respectively.
 BM Isolation and Cytospins Preparation  
 Approximately 5 ml of BM aspirate were collected from both 
upper anterior iliac crests into EDTA-treated tubes before surgery 
and immediately processed. Aspirate was washed in Hanks buffer 
(Biochrom AG, Germany) and centrifuged at 900 rpm for 10 min 
at 10   °   C to pellet the cellular fraction. Supernatant was discarded 
and cell pellet was then separated on a Ficoll-Hypaque density gra-
dient (1.077 g/mol) (Pharmacia, Germany). Mononuclear cells 
were collected from the interphase layer, counted and spun down 
at 150 g for 5 min at room temperature (RT) on a glass slide (1 × 
10 6 cells/spot) (SuperFrost ® Plus; Thermo Scientific). Cytospins 
were dried for 12–24 h at RT and then immediately stained or 
stored at –80  °  C.
 APAAP Staining and DTC Identification  
 Detection of tumor cells in the cytospin preparation was per-
formed as described previously, using the alkaline phosphatase 
anti-alkaline phosphatase technique (APAAP; DakoCtyomation, 
Denmark)  [30–32] . The murine antibody clone MOPC21 (Sigma, 
Germany) was used as IgG1 isotype-negative control to test the 
antibody reaction specificity (data not shown). For each patient, 2 
× 10 6 cells were screened manually by bright-field microscopy 




















   
   
   
   
   
   
   
   
   
   
   


























 CISH Staining and HER2 Detection 
 Amplification of the HER2 gene was detected using the chro-
mogenic in situ hybridization (CISH) method performed on all 
slides showing CK-positive DTCs. The samples were stained using 
the Zymed SPoT-Light HER2 CISH TM kit (Zymed ® Laboratories, 
USA), according to the manufacturer’s instruction. In brief, DTCs 
were incubated for 10 min at 65   °   C with 2 × saline sodium citrate 
(SSC) buffer, digested with pepsin for 5 min at 37   °   C and washed 
twice for 4 min in Phosphate Buffer Saline (PBS; Biochrom AG, 
Germany). Cells were then fixed in 4% paraformaldehyde (pH 7.2) 
for 2 min and washed again twice for 4 min in PBS, dehydrated in 
three graded ethanol series (70, 96, and 100%, 2 min each) and air 
dried for at least 20 min. Cells were then incubated with 70% for-
mamid/2% SSC plus 10 drops of 0.2  M HCl for 90 s at 68  °  C, again 
dehydrated in three graded ethanol series (70, 96, and 100%, 2 min 
each) and finally air dried for at least 20 min. After application of 
10 μl of Spot-Light HER2 DNA probe (Zymed Laboratories, USA), 
the slides were coverslipped, sealed with rubber cement, incubated 
for 5 min at 95  °  C and then stored in a humidified chamber at 37  °  C 
overnight. The slides were finally washed once in 0.5 × SSC for 
5 min at 72   °   C, 3 times in 0.05% Tween20-PBS for 2 min at RT, 3 
times in deionized water for 2 min at RT. Immunodetection was 
performed using the CISH detection kit (Zymed Laboratories, 
USA). Chromogenic detection of HER2 amplification was achieved 
using a standard bright-field microscope (Axiophot; Carl Zeiss, 
Germany) with a 40-fold magnification. The HER2 gene was con-
sidered amplified when at least 4 intranuclear signals were detect-
ed per cell.
 Statistical Analysis 
 Patients were classified as having a HER2-positive DTC status 
when at least one HER2-positive DTC was detected. Statistical 
analysis was performed using the SPSS 15.0 software (SPSS Inc., 
Chicago, Ill., USA). The χ 2 test was used to analyze the correlation 
between the HER2 status of DTCs and the different patients’ clin-
icopathological characteristics. All p values were two sided. p val-
ues <0.05 were considered statistically significant. 
 Results 
 Primary Tumor and Patients’ Characterization 
 In total, 232 BM aspirates were obtained from 156 BC 
patients. The median age at the primary diagnosis was 
56.5 years (range 33–80). A total of 92 (59%) patients were 
diagnosed with primary tumor at an early stage (T1a–c), 
while 61 (39.1%) at a later stage (T2–T4). Fifty-eight 
(37.2%) patients were node positive (pN1–3), and 86 
(55.1%) were node negative (pN0). Most patients showed 
G2–G3 grading (n = 135, 86.5%), while only 15 (9.6%) 
showed G1 grading. Primary tumors (n = 151) were found 
to be ER positive (n = 114, 75.5%) or PR positive (n = 96, 
63.6%). Finally, 62 (39.7%) primary tumors (n = 156) 
were classified as HER2 0 and 92 (58.9%) as HER2 1+ to 
3+. Forty-one (26.3%) patients were premenopausal, 112 
(71.8%) postmenopausal and 3 (1.9%) perimenopausal. 
All of them underwent surgery: 128 (82.1%) received con-
servative surgery, while 28 (17.9%) mastectomy. Con-
cerning the therapeutic regimen, 134 (85.9%) patients 
were treated with radiotherapy, 66 (42.3%) with endo-
crine therapy, 51 (32.7%) with chemotherapy, 22 (14.1%) 
with combined endocrine and chemotherapy, and 17 
(10.9%) did not receive any treatment. None of the pa-
tients was treated with Trastuzumab or any other HER2-
targeted agent at primary diagnosis. Finally, within the 
entire patient cohort, only 8 (5.1%) patients presented 
distant metastasis at the time of first diagnosis and 9 
(5.8%) showed local recurrence at follow-up (online 
 suppl. table 1). The median observation time after pri-
mary diagnosis was 20 months (range 6–327). 
 Detection of the HER2 Status of DTCs and 
Primary Tumor  
 A total of 89 BM samples were found positive for DTCs 
at the time of first diagnosis ( table 1 ). In 31 (34.8%) DTC-
positive samples at least one HER2-positive DTC was de-
tected, while the remaining 58 (65.2%) were HER2-nega-
tive. In the same sample group, only 17 (19.1%) primary 
tumors showed a positive HER2 status, while all others 
(n = 72, 80.9%) resulted negative. Comparing the HER2 
status of DTCs and the primary tumor, 61 (68.5%) pa-
tients showed a concordant HER2 status between prima-
 Table 1.  Detection of HER2 on the primary tumor and DTCs (n = 
89)








 Table 2. Comparison of the HER2 status between primary tumors 
and the corresponding DTCs at first diagnosis (n = 89)
HER2 status  Primary tumor
 Positive Negative Total
DTCs, n
Positive 10 (11.2%) 21 (23.6%) 31 (34.8%)
Negative 7 (7.8%) 51 (57.3%) 58 (65.2%)
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ry tumors and DTCs, being both HER2-negative (n = 51, 
57.3%) or HER2-positive (n = 10, 11.2%) ( table 2 ). How-
ever, 21 (23.6%) patients presented HER2-negative pri-
mary tumors and HER2-positive DTCs, while 7 (7.8%) 
HER2-positive primary tumors and HER2-negative 
DTCs. The correlation between the HER2 status of DTCs 
and the primary tumor was found statistically significant 
(p = 0.021). 
 Correlation between the HER2 Status of 
Primary Tumor and DTCs in Metastatic and 
Recurrent Patients  
 The HER2 status of DTCs was also analyzed in 6 of the 
8 patients found with distant metastases already at the 
first diagnosis. Four (66.6%) of them showed a concor-
dant HER2-positive status of DTCs and primary tumor, 
while 1 patient (16.7%) a concordant HER2-negative sta-
tus. One single patient (16.7%) was found with HER2-
negative DTCs and a HER2-positive primary tumor. The 
remaining 2 patients of this subgroup were not analyzed. 
A significant correlation between the HER2 status of 
DTCs and the primary tumor in patients with distant me-
tastases could not be found (p = 0.118) (online suppl. ta-
ble 2a). Furthermore, the HER2 status of DTCs was also 
measured in 6 of the 9 patients positive for local recur-
rence at follow-up. One (16.7%) single patient showed a 
concordant HER2-positive status of DTCs and primary 
tumor, while 3 (50%) patients a concordant HER2-nega-
tive status. Two patients (33.3%) presented HER2-nega-
tive DTCs and a HER2-positive primary tumor. The re-
maining 3 patients from this subgroup were not analyz-
able. A significant correlation between the HER2 status of 
DTCs and the primary tumor in patients with local recur-
rence could not be found (p = 0.27) (online suppl. ta-
ble 2b).
 Correlation between the HER2 Status of DTCs and 
Patients’ Characteristics 
 The DTC-positive cohort (n = 89) was stratified ac-
cording to the HER2 status of DTCs and the different pa-
tients’ characteristics. No significant correlation was ever 
found with primary tumor size (p = 0.39), nodal status 
(p = 0.97), tumor grading (p = 0.74), menopausal status 
(p = 0.40), or hormone receptor status (p = 0.24).
 Correlation between the HER2 Status of DTCs at 
Primary Diagnosis and after Chemotherapy 
 For 8 patients, BM aspirates were prepared at the time 
of first diagnosis and immediately after adjuvant che-
motherapy. Before therapy, most patients (n = 6, 75%) 
presented DTC-positive BM. Of these, 2 patients had 
HER2-positive DTCs, 3 had HER2-negative DTCs and 
1 was not analyzable for the HER2 status. Immediately 
after completion of chemotherapy, the BM of the same 
8 patients was analyzed again, and most patients (n = 5, 
62%) were still found DTC positive. Notably, the BM of 
the 2 patients found DTC negative during the first 
screening, resulted in both cases DTC positive. How-
ever, only one of them showed HER2-positive DTCs. Of 
the 6 patients with DTC-positive BM during the first 
screening, 3 confirmed their positivity also after the 
therapy, while the remaining 3 did not have any longer 
detectable DTCs. Two of the 3 persistently DTC-posi-
tive patients showed a HER2 status in agreement with 
the first finding. For the third one, no comparison was 
possible since no analysis was done at the time of first 
diagnosis. No significant correlation in the HER2 status 
was found between DTCs before and after chemothera-
py and the corresponding primary tumor (p = 0.136) 
(online suppl. table 3).
 Correlation between the HER2 Status of Primary 
Tumor and DTCs before Adjuvant Therapy and 
at Follow-Up 
 Eighteen patients underwent a double BM collection, 
before treatment and at follow-up, in average 14.9 months 
after the first collection. None of the patients showed local 
recurrence. Thirteen (72.2%) patients presented DTCs at 
the time of the first diagnosis: of these, 7 (70%) were 
HER2-negative and 3 (30%) HER2-positive. Three sam-
ples were not analyzable. At follow-up, 6 (33.3%) patients 
resulted positive for DTCs: of these, 4 (66.7%) were found 
HER2-positive and 2 (33.33%) HER2-negative. In all cas-
es but one, the HER2 status at primary diagnosis and fol-
low-up was concordant. Nevertheless, no significant cor-
relation between the HER2 status of DTCs and the pri-
mary tumor was found (p = 0.49 at the time of the first 
collection; p = 0.54 at the time of the second collection) 
(online suppl. table 4).
 Discussion 
 The detection of DTCs in BM of BC patients after sur-
gery and first line of therapy is correlated to an early and 
more aggressive recurrence, followed by a shorter sur-
vival  [33, 34] . Unfortunately, most DTCs are insensible to 
common adjuvant chemotherapy regimens, which tar-
gets only proliferating tumor cells  [35, 36] . The validity of 




















   
   
   
   
   
   
   
   
   
   
   


























MRD has been already proposed  [24, 27, 32] . However, 
in clinical practice, only primary tumor specimens are 
routinely checked for HER2 status and patients receive 
anti-HER2-based treatment depending only on these re-
sults. Therapies are decided on the hypothesis that MRD 
presents the same characteristics as the primary tumor, 
despite the fact that there is increasing evidence of the 
contrary  [26, 37, 38] . As a consequence, patients diag-
nosed with a HER2-negative primary tumor do not re-
ceive HER2-targeted agents, and cannot benefit of this 
treatment in case DTCs are instead HER2-positive. In or-
der to gain more insight into the significance of any cor-
relation between the HER2 status of DTCs isolated from 
BM of BC patients and the corresponding primary tu-
mors, we compared the HER2 status of DTCs with the 
primary tumors and other parameters such as patient’s 
characteristics, systemic therapy, presence of local recur-
rence or metastasis, unraveling heterogeneity in the 
HER2 status. DTCs were detected in 89 BM samples col-
lected from the 156 patients included in the study with a 
HER2 positivity rate of 34.8% (n = 31). Screening the 
same 89 patients with respect to the HER2 status of the 
primary tumor, only 17 (19.1%) were found positive. 
Comparing the results and correlating the HER2 status of 
DTCs and primary tumors, most of the patients (n = 61, 
68.5%) had a correspondent HER2 status. Interestingly, 
in the remaining 28 (31.4%) patients, a significant corre-
lation with respect to the HER2 status between the pri-
mary tumor and the DTCs was found (p = 0.021): 7 (7.8%) 
patients with HER2-positive primary tumors showed still 
HER2-negative DTCs, while 21 (23.6%) patients with 
HER2-negative primary tumor presented HER2-positive 
DTCs (p = 0.021). No significant correlation was found 
between the HER2 status of DTCs and primary tumor 
with respect to primary tumor size (p = 0.39), nodal status 
(p = 0.97), tumor grading (p = 0.74), menopausal status 
(p = 0.40) or hormone receptor status (p = 0.24). In addi-
tion, no significant correlation was found with respect to 
local recurrence (p = 0.27), metastasis (p = 0.118) or che-
motherapy (p = 0.136). This study presented some limita-
tions, such as the retrospective sampling and the hetero-
geneous patient cohort, not treated according to the ac-
tual guidelines; however, the results are clinically relevant. 
Immunophenotyping changes can be connected to CTCs’ 
and DTCs’ intravasation and secondary tissue coloniza-
tion  [39] . Discrepancies in the HER2 status between pri-
mary tumor and metastasis have been already described 
 [32, 40–43] . Several studies underlined a discrepancy also 
between primary tumors and CTCs both in early and 
metastatic BC patients  [44–46] . In this study, a clear dis-
cordance was found between primary tumor and DTCs. 
The acquisition of HER2 amplification in DTCs, while 
the primary tumor is negative, can be explained with a 
selective advantage conferred by HER2 to DTCs during 
dissemination  [21, 25, 47–50] , or with a higher tendency 
of the HER2-positive DTC clones to detach from the pri-
mary tumor and to spread  [25, 48–52] . We found that 
23.6% of patients presented a HER2-negative primary tu-
mor and HER2-positive DTCs. For patients’ manage-
ment, this finding is clinically relevant, since this patients’ 
group was not treated with HER2-targeted agents, al-
though they could have benefit from the therapy due to 
the HER2 positive status of the DTCs. In the latest years, 
the use of HER2-targeting agents has raised much interest 
to treat not only primary tumors but also CTCs/DTCs. 
Trastuzumab has been already shown to target chemo-
therapy-resistant cytokeratin-positive cells in the periph-
eral blood and BM of patients with BC  [53] . In addition, 
several clinical trials such as the German multicenter 
study Detect III (NCT01619111) and the European mul-
ticenter study TreatCTC (NCT01548677) are already fo-
cusing on the clinical impact of Lapatinib and Trastu-
zumab on BC patients presenting CTCs  [54] . Interest-
ingly, we found that 7.8% of the patients were 
HER2-positive on primary tumor and negative on DTCs. 
Detection of HER2-negative DTCs in BM with corre-
sponding HER2-positive primary tumors is difficult to 
rationalize. Loss of the phenotype could be linked to the 
selective pressure given by the therapy. However, in this 
case, the sampling was performed before adjuvant thera-
py; therefore, the shift in the phenotype was independent 
of the treatment. More studies should be performed to 
exclude any sampling error and to rationalize these find-
ings.
 Conclusion 
 This study showed a significant grade of discordance 
in the HER2 status between primary tumors and DTCs as 
found in the enrolled patient cohort. Importantly, a rel-
evant number of originally HER2-negative patients pre-
sented HER2-positive DTCs. Amplification of the HER2 
gene in persisting DTCs could be a valid method to strat-
ify patients for a better personalized treatment. In par-
ticular, patient stratification for new targeted agents 
against HER2, such as specific antibodies, could be con-
sidered as an individualized treatment option even for 
those patients who present HER2-negative primary tu-
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